Trilogy International Partners Inc T.TRL.WT.A

RE:Article

[LTOWNER]

Yes, the author is a momentum player, and that is what we are seeing here.  It's a strategy that could care less on approval or non-approval.

He says: "It is important to note, however, that while I made opinions as to the potential for the FDA to approve some companies, that we are not concerned all that much on whether or not the company ultimately obtains FDA approval. A prudent momentum trader will have sold well in advance of any FDA approval decision, or in such cases any Advisory Committee decisions."